A governing principle within the doctrines of international law on food safety is reflected in the words “The importance of the precautionary measures should not be played down on the grounds that the risk is not proven.” The collateral damage from not adhering to the precautionary principle is partially reflected in the numbers. In 1998, the number of Crohn’s disease afflicted individuals numbered 358,000. In 2006, this number was 560,000. In 2010, it was an estimated 800,000. In 2015, crude estimates place the figure above a million.
The 2015 expanded Hruska Postulate states that Crohn’s disease is the interaction of two immune responses to MAP occurring in different time frames. Learn more about these two immune responses and welcome our newest presenter, Gilles R. G. Monif, M.D.
For Clinicians
I was recently contacted by a physician with over 25 years of experience in designing and interpreting clinical trials who wanted to find out more about the role of mycobacteria in chronic inflammatory bowel disease. The following comments are quite interesting and should be reviewed by any physician remotely interested in advancing our understanding of the etiology, pathogenesis and treatment of Crohn’s disease. The conclusion is that there were major flaws in the design of the trial. Both sides can learn from this analysis.
Following the Selby Study analysis, an AMAT protocol is detailed for any clinician wishing to consider this therapy for Crohn’s disease.
Join us in our New Facebook Group
Welcome to The Crohn’s Infection on Facebook! Julie and Craig, the Site Administrators of TheCrohnsInfection.org, have created a private group to provide a social media outlet for those of you who wish to connect and discuss the information presented on our site. Please join us!
Crohn’s Disease Patient Raising Awareness of his Invisible Disease
Many of you may have seen the viral Facebook post by Ste Walker, a young man who detailed his battle with Crohn’s disease and the public perception of this illness. Rather than give up, Ste has courageously started a new campaign to bring awareness to the plight of Crohn’s disease patients around the world. Read on to learn more about Ste’s fight against Crohn’s and his #SickButInvisible Campaign.
GeneThera Press Release Details Expansion Into Crohn’s Disease
Dr. Tony Milici, GeneThera founder and CEO, announced his company’s expansion into the Crohn’s disease research field in a press release on January 25, 2016. GeneThera is dedicated to improving food safety by applying the latest molecular technologies to eradicate zoonotic diseases (those which cross from animals to the human population) such as Johne’s disease. Since it has long been thought that Johne’s disease, which is caused by the pathogen Mycobacterium avium spp paratuberculosis (MAP), has a zoonotic link to Crohn’s disease, GeneThera’s research could provide critically needed solutions.